Adenoviral vector expressing ICP47 inhibits adenovirus-specific cytotoxic T lymphocytes in nonhuman primates

Molecular Therapy

Volumn 2, Issue 5, 2000, Pages 505-514

  Scaria, Abraham ^a   Sullivan, Jennifer A ^a   St George, Judith A ^a   Kaplan, Johanne M ^a   Lukason, Michael J ^a   Morris, James E ^a   Plog, Malinda ^a   Nicolette, Charles ^a   Gregory, Richard J ^a   Wadsworth, Samuel C ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Adenoviral vector; CTLs; ICP47; MHC class I; Natural killer cells

Indexed keywords

ADENOVIRIDAE; ANIMALIA; HERPES; MACACA MULATTA; PRIMATES; SIMPLEXVIRUS;

CFTR PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; ICP47 PROTEIN, HERPES SIMPLEX VIRUS; IMMEDIATE EARLY PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; CELL CULTURE; CELL LINE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; LUNG; MACACA; METABOLISM; NATURAL KILLER CELL; TRANSGENE; VIROLOGY;

ADENOVIRIDAE; ANIMALS; CELL LINE; CELLS, CULTURED; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE EXPRESSION; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMEDIATE-EARLY PROTEINS; KILLER CELLS, NATURAL; LUNG; MACACA MULATTA; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES; VIRAL PROTEINS;

EID: 0034321754     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0197     Document Type: Article

References (51)

1. Rosenfeld, M. A., et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155.
2. Smith, T. A. G., et al. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Gene Ther. 5: 397-402.
3. Zabner, J., et al. (1994). Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat. Genet. 6: 75-83.
4. Dai, Y, Schwarz, E. M., Gu, D., Zhang, W., Sarvetnick, N., and Verma, I. M. (1995). Cellular and humoral responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long term expression. Proc. Natl. Acad. Sci. USA 92: 1401-1405.
5. Tripathy, S. K., Black, H. B., Goldwasser, E., and Leiden, J. M. (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus. Nat. Med. 2: 545-550.
6. Connelly, S., et al. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91: 3273-3281.
7. Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A. E., and Welsh, M. J. (1993). Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelium of patients with cystic fibrosis. Cell 75: 207-216.
8. Crystal, R. G., et al. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8: 42-51.
9. Yang, Y., Nunes, F. A., Berencsi, K., Gonczol, E., Engelhardt. J. F., and Wilson, J. M. (1994). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7: 362-369.
10. Yei, S., Mittereder, N., Tang, K., O'Sullivan, C., and Trapnell, B. C. (1994). Adenovirus mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1: 192-200.
11. Engelhardt, J. F., Ye, X., Doranz, B., and Wilson, J. M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91: 6196-6200.
12. Yang, Y., Li, Q., Ertl, H. C. J., and Wilson, J. M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69: 2004-2015.
13. Yang, Y., Xiang, Z., Ertl, H. C. J., and Wilson, J. M. (1995). Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA 92: 7257-7261.
14. Zsengeller, Z. K., et al. (1995). Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu-nu) mice. Hum. Gene Ther. 6: 457-467.
15. Yang, Y., Su, Q., and Wilson, J. M. (1996). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol. 70: 7209-7212.
16. Scaria, A., St. George, J. A., Jiang, C., Kaplan, J. M., Wadsworth, S. C., and Gregory, R. J. (1998). Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium. J. Virol. 72: 7302-7309.
17. Kaplan, J. M, et al. (1997). Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8: 45-56.
18. Armentano, D., et al. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71: 2408-2416.
19. Morral, N., O'Neal, W., Zhou, H., Langston, C., and Beaudet, A. L. (1997). Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a-deleted vectors. Hum. Gene Ther. 8: 1275-1286.
20. Quin, L., Ding, Y., Pahud, D. R., Chang, E., Imperiale, M. J., and Bromberg, J. S. (1997). Promoter attenuation in gene therapy: Interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum. Gene Ther. 8: 2019-2029.
21. Wang, Q., Greenburg, G., Bunch, D., Farson, D., and Finer, M. H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 4: 393-400.
22. Hu, H., Serra, D., and Amalfitano, A. (1999). Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum. Gene Ther. 10: 355-364.
23. Haecker, S. E., et al. (1996). In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum. Gene Ther. 7: 1907-1914.
24. Chen, H. H., Mack, L. M., Kelly, R., Ontell, M., Kochanek, S., and Clemens, P. R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. USA 94: 1645-1650.
25. Schiedner, G., et al. (1998). Genomic DNA transfer with high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18: 180-183.
26. Morral, N., et al. (1999). Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl. Acad. Sci. USA 96: 12816-12821.
27. Kay, M. A., et al. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration. Nat. Genet. 11: 191-197.
28. Poller, W., et al. (1996). Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 3: 521-530.
29. Yang., Y., Su, Q., Grewal, I. S., Schilz, R., Flavell, R. A., and Wilson, J. M. (1996). Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung. J. Virol. 70: 6370-6377.
30. Scaria, A., et al. (1997). Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse lung. Gene Ther. 4: 611-617.
31. Kaplan, J. M., and Smith, A. E. (1997). Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum. Gene Ther. 8: 1095-1104.
32. York, I. A., Roop, C., Andrews, D. W., Riddell, S. R., Graham, F. L., and Johnson, D. C. (1994). A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell 77: 525-535.
33. Hill, A., et al. (1995). Herpes simplex virus turns off the TAP to evade host immunity. Nature 375: 411-415.
34. Fruh, K., et al. (1995). A viral inhibitor of peptide transporters for antigen presentation. Nature 375: 415-418.
35. Jugovic, P., Hill, A. M., Tomazin, R., Ploegh, H., and Johnson, D. C. (1998). Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47. J. Virol. 72: 5076-5084.
36. Kaplan, J. M., et al. (1999). Induction of anti-tumor activity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163: 699-707.
37. Clay, T. M., et al. (1999). Changes in the fine specificity of gp100 (209-217).-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue, J. Immunol. 162: 1749-1755.
38. Wadsworth, S. C., Zhou, H., Smith, A. E., and Kaplan, J. M. (1997). Adenovirus vector-infected cells can escape adenovirus antigen-specific cytotoxic T-lymphocyte killing in vivo. J. Virol. 71: 5189-5196.
39. Barr, D., et al. (1995). Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 2: 151-155.
40. Michou, A. I., Santoro, L., Christ, M., Julliard, V., Pavirani, A., and Mehtali, M. (1997). Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Ther. 4: 473-482.
41. Franksson, L., George, E., Powis, S., Butcher, G., Howard, J., and Karre, K.(1993). Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. J. Exp. Med. 177: 201-205.
42. Natuk, R. J., and Welsh, R. M. (1987). Accumulation and chemotaxis of natural killer/large granular lymphocytes at sites of virus replication. J. Immunol. 138: 877-883.
43. Biron, C. A. (1997). Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 9: 24-34.
44. Glas, R., et al. (2000). Recruitment and activation of natural killer cells in vivo determined by the target cell phenotype: An adaptive component of NK cell-mediated responses. J. Exp. Med. 191: 129-138.
45. Harms, J. S., and Splitter, G. A. (1995). Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther. 6: 1291-1297.
46. Wold, W. S. M., Tollefson, A. E., and Hermiston, T. W. (1994). Adenovirus proteins that subvert host defenses. Trends Microbiol. 2: 437-443.
47. Ploegh, H. L. (1998). Viral strategies of immune evasion. Science. 280: 248-253.
48. Schowalter, D. B., Tubb, J. C., Liu, M., Wilson, C. B., and Kay, M. A. (1997). Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther. 4: 351-360.
49. Lee, M. G., Abina, M. A., Haddada, H., and Perricaudet, M. (1995). The constitutive expression of the immunomodulatory gp19K protein in E1-, E3-adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 2: 256-262.
50. Bruder, J. T., Jie, T., McVey, D. L., and Kovesdi, I. (1997). Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J. Virol. 71: 7623-7628.
51. Ilan, Y., et al. (1997). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. USA 94: 2587-2592.